Amryt Pharma, a company with ambitions to become a leader in the rare disease space, has set its sights on the Middle East. David Allmond, the company’s chief commercial officer spoke to the Pink Sheet about the advantages of marketing authorization, the benefits of local partners and how to get the value proposition right for the payer.
Lojuxta (lomitapide), a treatment for adults with homozygous familial hypercholesterolemia (HoFH), a rare and life-threatening condition that impairs the body's...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?